Recent developments in drug therapy for aplastic anemia

Area of Science:

• Hematology
• Immunosuppressive Therapy
• Aplastic Anemia Research

Background:

• Aplastic anemia (AA) is a rare, severe bone marrow failure disorder.
• Treatment options for AA patients ineligible for stem cell transplant (SCT) are limited.
• Optimizing immunosuppressive therapy (IST) is crucial for improving outcomes in non-SCT candidates.

Purpose of the Study:

• To review recent developments in IST for aplastic anemia (AA) patients.
• To evaluate front-line, salvage, and novel treatment options.
• To focus on response rates (RRs) and overall survival (OS) in non-SCT candidates.

Main Methods:

• Conducted a PubMed literature search from 1977 to June 2014.
• Utilized search terms including aplastic anemia, horse antithymocyte globulin (hATG), rabbit ATG (rATG), and cyclosporine (CSA).
• Evaluated English-language studies on IST for AA in non-SCT candidates.

Main Results:

• Addition of CSA and corticosteroids to hATG improves RRs, decreases relapse rates, and improves 5-year OS.
• hATG demonstrated superior RRs, relapse rates, and OS compared to rATG in front-line settings.
• rATG is effective for salvage therapy when hATG fails or is unavailable; daclizumab, alemtuzumab, and eltrombopag show potential in select cases.

Conclusions:

• Horse antithymocyte globulin (hATG) combined with methylprednisolone and CSA is the recommended front-line IST for AA.
• Rabbit antithymocyte globulin (rATG) is reserved for salvage therapy.
• Novel agents like daclizumab, alemtuzumab, and eltrombopag require further clinical trials to define their role in AA treatment.